Literature DB >> 27077753

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model.

Assaf Dotan1, Israel Kremer2, Orly Gal-Or3, Tami Livnat4, Arie Zigler5, Dan Bourla3, Dov Weinberger6.   

Abstract

Myopic individuals, especially those with severe myopia, are at higher-than-normal risk of cataract, glaucoma, retinal detachment and chorioretinal abnormalities. In addition, pathological myopia is a common irreversible cause of visual impairment and blindness. Our study demonstrates the effect of scleral crosslinking using riboflavin and ultraviolet-A radiation on the development of axial myopia in a rabbit model. The axial length of the eyeball was measured by A-scan ultrasound in New Zealand white rabbits aged 13 days (male and female). The eye then underwent 360° conjunctival peritomy with scleral crosslinking, followed by tarsorrhaphy. Axial elongation was induced in 13 day-old New Zealand rabbits by suturing their right eye eyelids (tarsorrhaphy). The eyes were divided into quadrants, and every quadrant had two scleral irradiation zones, each with an area of 0.2 cm² and a radius of 4 mm. Crosslinking was performed by dropping 0.1% dextran-free riboflavin-5-phosphate onto the irradiation zones 20 sec before ultraviolet-A irradiation and every 20 sec during the 200 sec irradiation time. UVA radiation (370 nm) was applied perpendicular to the sclera at 57 mW/cm² (total UVA light dose, 57 J/cm²). Tarsorrhaphies were removed on day 55, followed by repeated axial length measurements. This study demonstrates that scleral crosslinking with riboflavin and ultraviolet-A radiation effectively prevents occlusion-induced axial elongation in a rabbit model.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27077753      PMCID: PMC4841336          DOI: 10.3791/53201

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  25 in total

Review 1.  Toward controlling myopia progression?

Authors:  C F Wildsoet; T T Norton
Journal:  Optom Vis Sci       Date:  1999-06       Impact factor: 1.973

2.  Increase in axial length of the macaque monkey eye after corneal opacification.

Authors:  T N Wiesel; E Raviola
Journal:  Invest Ophthalmol Vis Sci       Date:  1979-12       Impact factor: 4.799

3.  A retrospective study of myopia progression in adult contact lens wearers.

Authors:  Mark A Bullimore; Lisa A Jones; Melvin L Moeschberger; Karla Zadnik; Rick E Payor
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-07       Impact factor: 4.799

4.  Long-term biomechanical properties of rabbit sclera after collagen crosslinking using riboflavin and ultraviolet A (UVA).

Authors:  Gregor Wollensak; Elena Iomdina
Journal:  Acta Ophthalmol       Date:  2008-09-18       Impact factor: 3.761

5.  Time course of rhesus lid-suture myopia.

Authors:  P R Greene; D L Guyton
Journal:  Exp Eye Res       Date:  1986-06       Impact factor: 3.467

6.  Scleral cross-linking using riboflavin and ultraviolet-a radiation for prevention of progressive myopia in a rabbit model.

Authors:  Assaf Dotan; Israel Kremer; Tami Livnat; Arie Zigler; Dov Weinberger; Dan Bourla
Journal:  Exp Eye Res       Date:  2014-08-08       Impact factor: 3.467

Review 7.  Myopia and associated pathological complications.

Authors:  Seang-Mei Saw; Gus Gazzard; Edwin Chan Shih-Yen; Wei-Han Chua
Journal:  Ophthalmic Physiol Opt       Date:  2005-09       Impact factor: 3.117

8.  Normal and staphylomatous sclera of high myopia. An electron microscopic study.

Authors:  B J Curtin; T Iwamoto; D P Renaldo
Journal:  Arch Ophthalmol       Date:  1979-05

9.  Collagen crosslinking of human and porcine sclera.

Authors:  Gregor Wollensak; Eberhard Spoerl
Journal:  J Cataract Refract Surg       Date:  2004-03       Impact factor: 3.351

10.  Prevention of collagen crosslinking increases form-deprivation myopia in tree shrew.

Authors:  N A McBrien; T T Norton
Journal:  Exp Eye Res       Date:  1994-10       Impact factor: 3.467

View more
  7 in total

Review 1.  IMI - Report on Experimental Models of Emmetropization and Myopia.

Authors:  David Troilo; Earl L Smith; Debora L Nickla; Regan Ashby; Andrei V Tkatchenko; Lisa A Ostrin; Timothy J Gawne; Machelle T Pardue; Jody A Summers; Chea-Su Kee; Falk Schroedl; Siegfried Wahl; Lyndon Jones
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-02-28       Impact factor: 4.799

2.  Selective Equatorial Sclera Crosslinking in the Orbit Using a Metal-Coated Polymer Waveguide.

Authors:  Sheldon J J Kwok; Sarah Forward; Christian M Wertheimer; Andreas C Liapis; Harvey H Lin; Moonseok Kim; Theo G Seiler; Reginald Birngruber; Irene E Kochevar; Theo Seiler; Seok-Hyun Yun
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-06-03       Impact factor: 4.799

3.  Scleral ultrastructure and biomechanical changes in rabbits after negative lens application.

Authors:  Xiao Lin; Bing-Jie Wang; Yen-Chiao Wang; Ren-Yuan Chu; Jin-Hui Dai; Xing-Tao Zhou; Xiao-Mei Qu; Hong Liu; Hao Zhou
Journal:  Int J Ophthalmol       Date:  2018-03-18       Impact factor: 1.779

4.  Protective effects of riboflavin-UVA-mediated posterior sclera collagen cross-linking in a guinea pig model of form-deprived myopia.

Authors:  Ding Han; Mei-Nan He; Ying Zhu; Yan Zhang; Rui-Hua Wei
Journal:  Int J Ophthalmol       Date:  2021-03-18       Impact factor: 1.779

5.  Global Tendency and Frontiers of Research on Myopia From 1900 to 2020: A Bibliometrics Analysis.

Authors:  Mengyuan Shan; Yi Dong; Jingyi Chen; Qing Su; Yan Wan
Journal:  Front Public Health       Date:  2022-03-10

Review 6.  Effects of air pollution on myopia: an update on clinical evidence and biological mechanisms.

Authors:  Tianyi Yuan; Haidong Zou
Journal:  Environ Sci Pollut Res Int       Date:  2022-08-29       Impact factor: 5.190

7.  Minimally Invasive Repetitive UVA Irradiation along with Riboflavin Treatment Increased the Strength of Sclera Collagen Cross-Linking.

Authors:  Bo Xiao; Yanhua Chu; Hongyan Wang; Quanhong Han
Journal:  J Ophthalmol       Date:  2017-12-17       Impact factor: 1.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.